Financhill
Buy
55

FONR Quote, Financials, Valuation and Earnings

Last price:
$14.28
Seasonality move :
-0.08%
Day range:
$14.16 - $14.59
52-week range:
$12.00 - $18.68
Dividend yield:
0%
P/E ratio:
11.48x
P/S ratio:
0.89x
P/B ratio:
0.53x
Volume:
83.5K
Avg. volume:
34.3K
1-year change:
-7.6%
Market cap:
$90.3M
Revenue:
$102.9M
EPS (TTM):
$1.25

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
FONR
Fonar
-- -- -- -- --
APDN
Applied DNA Sciences
$1.2M -$3.00 27.47% -98.87% --
OCX
OncoCyte
$126.8K -$0.25 180.72% -33.33% $5.42
PRPH
ProPhase Labs
$2.5M -$0.18 3.99% -50% $13.80
VCYT
Veracyte
$111M $0.20 6.44% 332.6% $40.50
XWEL
XWELL
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
FONR
Fonar
$14.35 -- $90.3M 11.48x $0.00 0% 0.89x
APDN
Applied DNA Sciences
$0.52 -- $3.4M -- $0.00 0% 0.09x
OCX
OncoCyte
$3.25 $5.42 $92.9M -- $0.00 0% 14.73x
PRPH
ProPhase Labs
$0.36 $13.80 $15M -- $0.00 0% 1.95x
VCYT
Veracyte
$27.97 $40.50 $2.2B 68.22x $0.00 0% 4.77x
XWEL
XWELL
$0.86 -- $4.5M -- $0.00 0% 0.13x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
FONR
Fonar
-- 1.233 -- 9.69x
APDN
Applied DNA Sciences
-- 5.301 -- 3.97x
OCX
OncoCyte
-- -1.798 -- 3.57x
PRPH
ProPhase Labs
22.08% -4.436 25.51% 0.84x
VCYT
Veracyte
-- 3.551 -- 4.54x
XWEL
XWELL
-- -0.848 -- 1.41x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
FONR
Fonar
$12.1M $3.7M 5.32% 5.33% 15.23% $2.5M
APDN
Applied DNA Sciences
$370.9K -$3.5M -84.02% -84.02% -352.03% -$3.4M
OCX
OncoCyte
$1.3M -$5.9M -693.81% -693.81% -310.66% -$6.2M
PRPH
ProPhase Labs
$526K -$3.7M -101.67% -144.22% -289.24% -$3.4M
VCYT
Veracyte
$79.5M $1.2M 2.85% 2.85% 1.02% $3.5M
XWEL
XWELL
$1.3M -$3.2M -153.74% -153.74% -64.9% -$4.6M

Fonar vs. Competitors

  • Which has Higher Returns FONR or APDN?

    Applied DNA Sciences has a net margin of 9.23% compared to Fonar's net margin of -336%. Fonar's return on equity of 5.33% beat Applied DNA Sciences's return on equity of -84.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    FONR
    Fonar
    44.52% $0.37 $160.3M
    APDN
    Applied DNA Sciences
    37.71% -$15.35 $10.2M
  • What do Analysts Say About FONR or APDN?

    Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 289979.29%. Given that Applied DNA Sciences has higher upside potential than Fonar, analysts believe Applied DNA Sciences is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    FONR
    Fonar
    0 0 0
    APDN
    Applied DNA Sciences
    0 1 0
  • Is FONR or APDN More Risky?

    Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.491%.

  • Which is a Better Dividend Stock FONR or APDN?

    Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FONR or APDN?

    Fonar quarterly revenues are $27.2M, which are larger than Applied DNA Sciences quarterly revenues of $983.4K. Fonar's net income of $2.5M is higher than Applied DNA Sciences's net income of -$3.3M. Notably, Fonar's price-to-earnings ratio is 11.48x while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.89x versus 0.09x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FONR
    Fonar
    0.89x 11.48x $27.2M $2.5M
    APDN
    Applied DNA Sciences
    0.09x -- $983.4K -$3.3M
  • Which has Higher Returns FONR or OCX?

    OncoCyte has a net margin of 9.23% compared to Fonar's net margin of -312.02%. Fonar's return on equity of 5.33% beat OncoCyte's return on equity of -693.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    FONR
    Fonar
    44.52% $0.37 $160.3M
    OCX
    OncoCyte
    61.97% -$0.26 $10.2M
  • What do Analysts Say About FONR or OCX?

    Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand OncoCyte has an analysts' consensus of $5.42 which suggests that it could grow by 66.67%. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    FONR
    Fonar
    0 0 0
    OCX
    OncoCyte
    1 2 0
  • Is FONR or OCX More Risky?

    Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison OncoCyte has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.749%.

  • Which is a Better Dividend Stock FONR or OCX?

    Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FONR or OCX?

    Fonar quarterly revenues are $27.2M, which are larger than OncoCyte quarterly revenues of $2.1M. Fonar's net income of $2.5M is higher than OncoCyte's net income of -$6.7M. Notably, Fonar's price-to-earnings ratio is 11.48x while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.89x versus 14.73x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FONR
    Fonar
    0.89x 11.48x $27.2M $2.5M
    OCX
    OncoCyte
    14.73x -- $2.1M -$6.7M
  • Which has Higher Returns FONR or PRPH?

    ProPhase Labs has a net margin of 9.23% compared to Fonar's net margin of -209.38%. Fonar's return on equity of 5.33% beat ProPhase Labs's return on equity of -144.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    FONR
    Fonar
    44.52% $0.37 $160.3M
    PRPH
    ProPhase Labs
    36.76% $0.11 $19.4M
  • What do Analysts Say About FONR or PRPH?

    Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3733.33%. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    FONR
    Fonar
    0 0 0
    PRPH
    ProPhase Labs
    0 0 0
  • Is FONR or PRPH More Risky?

    Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.472, suggesting its less volatile than the S&P 500 by 147.175%.

  • Which is a Better Dividend Stock FONR or PRPH?

    Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FONR or PRPH?

    Fonar quarterly revenues are $27.2M, which are larger than ProPhase Labs quarterly revenues of $1.4M. Fonar's net income of $2.5M is lower than ProPhase Labs's net income of $4M. Notably, Fonar's price-to-earnings ratio is 11.48x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.89x versus 1.95x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FONR
    Fonar
    0.89x 11.48x $27.2M $2.5M
    PRPH
    ProPhase Labs
    1.95x -- $1.4M $4M
  • Which has Higher Returns FONR or VCYT?

    Veracyte has a net margin of 9.23% compared to Fonar's net margin of 6.16%. Fonar's return on equity of 5.33% beat Veracyte's return on equity of 2.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    FONR
    Fonar
    44.52% $0.37 $160.3M
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
  • What do Analysts Say About FONR or VCYT?

    Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand Veracyte has an analysts' consensus of $40.50 which suggests that it could grow by 44.8%. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    FONR
    Fonar
    0 0 0
    VCYT
    Veracyte
    7 2 1
  • Is FONR or VCYT More Risky?

    Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison Veracyte has a beta of 2.145, suggesting its more volatile than the S&P 500 by 114.466%.

  • Which is a Better Dividend Stock FONR or VCYT?

    Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FONR or VCYT?

    Fonar quarterly revenues are $27.2M, which are smaller than Veracyte quarterly revenues of $114.5M. Fonar's net income of $2.5M is lower than Veracyte's net income of $7M. Notably, Fonar's price-to-earnings ratio is 11.48x while Veracyte's PE ratio is 68.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.89x versus 4.77x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FONR
    Fonar
    0.89x 11.48x $27.2M $2.5M
    VCYT
    Veracyte
    4.77x 68.22x $114.5M $7M
  • Which has Higher Returns FONR or XWEL?

    XWELL has a net margin of 9.23% compared to Fonar's net margin of -67.19%. Fonar's return on equity of 5.33% beat XWELL's return on equity of -153.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    FONR
    Fonar
    44.52% $0.37 $160.3M
    XWEL
    XWELL
    18.78% -$1.00 $3.4M
  • What do Analysts Say About FONR or XWEL?

    Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 712.91%. Given that XWELL has higher upside potential than Fonar, analysts believe XWELL is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    FONR
    Fonar
    0 0 0
    XWEL
    XWELL
    0 0 0
  • Is FONR or XWEL More Risky?

    Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

  • Which is a Better Dividend Stock FONR or XWEL?

    Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FONR or XWEL?

    Fonar quarterly revenues are $27.2M, which are larger than XWELL quarterly revenues of $7M. Fonar's net income of $2.5M is higher than XWELL's net income of -$4.7M. Notably, Fonar's price-to-earnings ratio is 11.48x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.89x versus 0.13x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FONR
    Fonar
    0.89x 11.48x $27.2M $2.5M
    XWEL
    XWELL
    0.13x -- $7M -$4.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
57
TNXP alert for May 29

Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.

Buy
70
AGFY alert for May 29

Agrify [AGFY] is up 18.95% over the past day.

Buy
87
SMR alert for May 29

NuScale Power [SMR] is down 0.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock